Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.

Journal:

Journal of Clinical Oncology

Published:

2026-01-24

DOI:

10.1200/jco-25-02176

Affiliations:

17

Authors:

31

Go to article

Institutions	Authors	Share
Guangdong Academy of Medical Sciences (Guangdong Provincial People’s Hospital), China	12.000000 12.000000	0.39
Foshan First People's Hospital, China	2.000000	0.06
Shantou Central Hospital, China	2.000000	0.06
The First Affiliated Hospital, SYSU, China	2.000000	0.06
First Affiliated Hospital, GDPU, China	1.000000	0.03
Dongguan People's Hospital, China	1.000000	0.03
State Key Laboratory of Traditional Chinese Medicine Syndrome, China	1.000000	0.03
Guangdong Zhaoqing No.1 People's Hospital, China	1.000000	0.03
Affiliated Hospital of Guangdong Medical University, GDMU, China	1.000000	0.03
Baotou Central Hospital, China	1.000000	0.03
Tungwah hospital, China	1.000000	0.03
Zhongshan City People's Hospital, China	1.000000	0.03
The Fifth Medical Center, PLAGH, China	1.000000	0.03
Tumor Hospital of Guangxi Medical University, China	1.000000	0.03
South China University of Technology (SCUT), China	1.000000	0.03
Guilin Municipal Hospital of Traditional Chinese Medicine, China	1.000000	0.03
Wuhan Union Hospital, HUST, China	1.000000	0.03

Interested in Oncology and Carcinogenesis?